Ascend dabigatran capsules recalled for failed impurity specification
Ascend Laboratories is recalling one lot of dabigatran etexilate capsules, 75 mg, 60-count, after a 12-month stability test found impurity levels outside the allowed limits. The out-of-specification results were for Impurity II, Impurity III, and total impurities. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls
What to do
- Talk to your pharmacist or prescriber before stopping this medicine.
- Check whether your capsules are Lot 25141585 with expiration date April 30, 2027, NDC 0904-7253-68, distributed by Major Pharmaceuticals, Indianapolis, IN.
- The notice doesn't say how to get a refund or replacement; contact Ascend Laboratories or the pharmacy where you bought it.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
This recall covers 3 products — see all of them.
Details
- Units affected
- 924 cartons x 12 x 6 x 10 (in blister pack)
- Illnesses reported
- None reported
- Manufactured in
- 135 Us Highway 202 206 Ste 15, N/A, Bedminster, NJ, United States
- Classification
- Class III
- Recall number
- D-0738-2026
In the FDA's words
- Description
- Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68. Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability Lot: 25141585, Exp. April 30, 2027. Distribution: USA Nationwide Affected quantity: 924 cartons x 12 x 6 x 10 (in blister pack)
- Hazard
- Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
3 products in this recall
The agency lists each product separately. Check every one you might have.
- Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai,…D-0737-2026 · 3,600 cartons x 6 x 10 (in blister pack)
- Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, IN… (this page)D-0738-2026 · 924 cartons x 12 x 6 x 10 (in blister pack)
- Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, I…D-0739-2026 · 936 cartons x 12 x 3 x 10 (in blister pack)
More from Ascend Laboratories
See all- Ascend amlodipine/olmesartan tablets recalled for failed dissolution
ModerateFDAOct 16, 2026